Journal of Reports in Pharmaceutical Sciences
Volume 12 · Issue 1 · e146804

OPEN PEER REVIEW

Investigation of Thrombolysis with Reteplase on Vital Signs, Right Ventricular Parameters and Clinical Symptoms of Patients with Acute Massive and Sub-massive Pulmonary Embolism

Fatemeh Jafari, Nazanin Hanafi Bojd, fateme mahdizadeh

SUBMITTED	REVISED	ACCEPTED	DOI
3 Apr 2024	13 Sep 2024	9 Oct 2024	10.5812/jrps-146804

About this report

This open peer review (OPR) report shows the public comments made on this article during peer review, by the reviewers, the associate editor and the editor-in-chief, for every revision round, together with the authors' replies. Comments appear only with the consent of the people who wrote them. Reviewers who chose to sign their report are named; the others are shown as "Referee". Comments are edited for language only, and confidential remarks to the editors are not included.

More about open peer review: brieflands.com/knowledgebase/opr

Contents

1 **Original submission** Referee 1, Associate Editor, Editor-in-Chief 2
2 **Revision 1** Referee 1, Associate Editor, Editor-in-Chief 3
Authors' reply to reviewers 4
Reviewer and editor comments 6

1 Original submission

3 comments · 23 Jul 2024 – 7 Aug 2024

Referee 1 Reviewer

MAJOR REVISION 23 Jul 2024

Dear
1. Please add the main results or methods in the abstract. Don't use statistical tests in the abstract.
2. Please write "average age ± standard deviation".
3. Please write the full name of each abbreviation (e.g., HR, RR, BP) the first time it is used, either in the abstract or in the rest of the text.
4. Please do not repeat results in the discussion. Paragraph 2 in the discussion duplicates the results. Please add differences and similarities between your results and those of previous studies and discuss the reasons and solutions.
5. Please add clinical significance to the results.
6. Please add limitations of the study at the end of the discussion.
7. The conclusion doesn't support the results.
8. Add the full name of each abbreviation below each table or figure.
9. For an original article, a minimum of 25 references is needed.

Associate Editor

MAJOR REVISION 7 Aug 2024

Dear Nazanin Hanafi Bojd

Thank you for submitting your manuscript entitled “Investigation of Thrombolysis with Reteplase on Vital Signs, Right Ventricular Parameters and Clinical Symptoms of Patients with Acute Massive and Submassive Pulmonary Embolism” to the Journal of Reports in Pharmaceutical Sciences.

As you can see, many major and minor comments have been raised by the anonymous peer reviewers. Therefore, we ask you to respond to all the comments raised point by point and revise the manuscript carefully. It is noteworthy that the revised article will be sent for re-review.

Editor-in-Chief

MAJOR REVISION 7 Aug 2024

Dear Nazanin Hanafi Bojd

Thank you for submitting your manuscript entitled “Investigation of Thrombolysis with Reteplase on Vital Signs, Right Ventricular Parameters and Clinical Symptoms of Patients with Acute Massive and Submassive Pulmonary Embolism” to the Journal of Reports in Pharmaceutical Sciences.

As you can see, many major and minor comments have been raised by the anonymous peer reviewers. Therefore, we ask you to respond to all comments raised point by point and revise the manuscript carefully. It is noteworthy that the revised article will be sent for re-review.

2

Revision 1

AUTHORS' RESPONSE TO REVIEWERS

Authors' reply to reviewers

The next pages contain the authors' point-by-point reply to the comments of this revision round, as submitted with the revised manuscript. It is published as the authors wrote it.

Reviewer 1:

Overall, the manuscript provides valuable insights into thrombolysis with reteplase in patients with acute pulmonary embolism requiring thrombolysis. This is well-written. However, I would like to highlight a few areas that could benefit from improvement and further clarification. I appreciate your efforts in conducting this study, and I believe that addressing these suggestions will further strengthen the manuscript.

1. Please specify the dosage of retplase administered.
   Reply: it is added.

2. The eligibility criteria for patients receiving retplase should be clearly defined. Additionally, it is important to mention the characteristics of ineligible patients, such as a history of bleeding, and so on.
   Reply: it is revised

3. Analyzing results based on patients with massive and sub-massive PE may be helpful.
   Reply: Currently it is not possible.

4. Please mention all abbreviations in the manuscript, such as RR, HR, DVT, CVA, BP, SpO2, etc., at their first occurrence
   Reply: it is mentioned.

5. Please include all abbreviations used in the table in the caption.
   Reply: it is mentioned

6. Please correct the mean (±SD) age of patients in Table 7.
   Reply: it is corrected.

7. It is not necessary to use two rows for "yes" and "no" in the tables. Simply stating the number and percentage of people with those conditions is sufficient.
   Reply: It is corrected.

Reviewer 2:

Dear

1. Please add the main results or methods in the abstract. Don't use statistical tests in the abstract.
   Reply: it is removed.
2. Please write "average age ± standard deviation".
   Reply: it is added.

3. Please write the full name of each abbreviation for the first time either in the abstract or the rest of the text such as (HR, RR, BP), ...

Reply: it is mentioned

3. Please do not repeat results in the discussion. Paragraph 2 in the discussion has a duplicate of the results. Please add differences and similarities between your results and those of previous studies and discuss the reasons and solutions.
   Reply: it is revised
4. Please add clinical significance to the results.
   Reply: it is added.

6. Please add limitations of the study at the end of the discussion.

Reply: it is added

8. Conclusion doesn't support results.
   Reply: it is revised.

8. Add the full name of each abbreviation below each table or figure.

Reply: it is added

9. For an original article, a minimum of 25 references is needed.
   Reply: it is added.

2 Revision 1

3 comments · 9 Oct 2024 – 9 Oct 2024

Referee 1 Reviewer

ACCEPT 9 Oct 2024

Dear
It is acceptable.

Associate Editor

ACCEPT 9 Oct 2024

I am writing to extend my heartfelt congratulations on the acceptance of your insightful article, "Investigation of Thrombolysis with Reteplase on Vital Signs, Right Ventricular Parameters and Clinical Symptoms of Patients with Acute Massive and Submassive Pulmonary Embolism," in "Journal of Reports in Pharmaceutical Sciences".

The depth of your research and the potential impact of your findings are truly commendable. Your work offers valuable contributions to the field and will undoubtedly serve as a significant resource for fellow researchers and clinicians.

Thank you for your dedication and hard work in advancing our understanding of thrombolysis and pulmonary embolism treatment.

Warm regards,
Editor of Journal of Reports in Pharmaceutical Sciences

Editor-in-Chief

ACCEPT 9 Oct 2024

I am writing to extend my heartfelt congratulations on the acceptance of your insightful article, "Investigation of Thrombolysis with Reteplase on Vital Signs, Right Ventricular Parameters and Clinical Symptoms of Patients with Acute Massive and Submassive Pulmonary Embolism," in "Journal of Reports in Pharmaceutical Sciences".

The depth of your research and the potential impact of your findings are truly commendable. Your work offers valuable contributions to the field and will undoubtedly serve as a significant resource for fellow researchers and clinicians.

Thank you for your dedication and hard work in advancing our understanding of thrombolysis and pulmonary embolism treatment.

Warm regards,
Editor of Journal of Reports in Pharmaceutical Sciences